Raised plasma hypoxanthine levels as a prognostic sign in preterm babies with respiratory distress syndrome treated with natural surfactant.
Plasma hypoxanthine concentration was measured in twelve preterm babies with respiratory distress syndrome (RDS) treated with 200 mg/kg of a porcine surfactant (Curosurf). Five of the babies died within one week and seven survived the neonatal period. Surviving babies had no significant changes in plasma hypoxanthine concentration throughout a one hour study period following the administration of surfactant. By contrast, in nonsurvivors the mean plasma hypoxanthine concentrations increased from 6.8 mumol/l before surfactant administration to 14.2 mumol/l 15 minutes after surfactant treatment. Survivors had a mean maximal increase in plasma hypoxanthine of 1.9 mumol/l 15-30 min factor surfactant treatment compared with 9.4 mumol/l in nonsurvivors (p < 0.05). The babies who developed intracranial hemorrhage had significantly higher maximal plasma hypoxanthine increase (mean 9.6 mumol/l) compared with babies who did not develop intracranial hemorrhage (mean 1.1 mumol/l) (p < 0.01). The combination of high PaO2 and high hypoxanthine concentration could lead to an increased production of oxygen radicals which might be harmful. We conclude that plasma hypoxanthine concentration may serve as an indicator of the prognosis in preterm babies treated with natural surfactant. Further, it seems important to reduce oxygen supplementation as soon as surfactant is given to possibly limit oxygen radical production.
Saugstad
O D
OD
Department of Pediatrics, Rikshospitalet, Oslo, Norway.
Tubman
T R
TR
Gloppestad
K
K
Halliday
H L
HL
Oyasaeter
S
S
Curstedt
T
T
Robertson
B
B
D015415:Biomarkers / Q000097:blood; D002543:Cerebral Hemorrhage / Q000097:blood / Q000209:etiology; D006801:Humans; D019271:Hypoxanthine; D007042:Hypoxanthines / Q000097:blood*; D007231:Infant, Newborn; D007234:Infant, Premature; D010100:Oxygen / Q000097:blood; D011379:Prognosis; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000097:blood* / Q000150:complications / Q000188:drug therapy*
D015415:Biomarkers; D007042:Hypoxanthines; D011663:Pulmonary Surfactants; D019271:Hypoxanthine; D010100:Oxygen